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Germ line mutations in breast cancer gene 1 (BRCA1) predispose women to breast and ovarian cancers. Although
BRCA1 is involved in many important biological processes, the function of BRCA1 in homologous recombination
(HR) mediated repair is considered one of the major mechanisms contributing to its tumor suppression activity, and
the cause of hypersensitivity to poly(ADP-ribose) polymerase (PARP) inhibitors when BRCA1 is defective. Mounting
evidence suggests that the mechanism of repairing DNA double strand breaks (DSBs) by HR is different than the
mechanism operating when DNA replication is blocked. Although BRCA1 has been recognized as a central
component in HR, the precise role of BRCA1 in HR, particularly under replication stress, has remained largely
unknown. Given the fact that DNA lesions caused by replication blockages are the primary substrates for HR in
mitotic cells, functional analysis of BRCA1 in HR repair in the context of replication stress should benefit our
understanding of the molecular mechanisms underlying tumorigenesis associated with BRCA1 deficiencies, as well
as the development of therapeutic approaches for cancer patients carrying BRCA1 mutations or reduced BRCA1
expression. This review focuses on the current advances in this setting and also discusses the significance in
tumorigenesis and cancer therapy.
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(GC) versus crossover
DNA lesions result from errors in normal DNA repli-
cation, production of reactive oxygen species, and ex-
posure to ultraviolet rays and ionizing radiation (IR).
The damage induced by endogenous or exogenous in-
sults can be base damages, single strand breaks (SSBs),
DSBs, and intrastrand or interstrand cross-links [1]. The
inability to properly repair damaged DNA can lead to
genomic instability, a hallmark of cancer. To avoid the
consequence of unrepaired DNA damage, multiple types
of DNA repair mechanisms exist in cells to repair the
various types of DNA damage on a regular basis, includ-
ing base excision repair (BER), nucleic acid excision re-
pair (NER), HR, single strand annealing (SSA), mismatch
repair (MMR) and non-homologous end joining (NHEJ)Correspondence: junran.zhang@case.edu
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reproduction in any medium, provided the or[1]. HR is required for repairing multiple types of DNA
damage including single stranded DNA (ssDNA), DSBs
and DNA cross-links. In addition, HR is a critical mech-
anism for recovery of stalled or broken DNA replication
forks. Certain genetic alterations, such as BRCA1 and
BRCA2 mutations, are associated with increased risk of
malignancy and enhanced sensitivity to chemotherapeu-
tic agents, including PARP inhibitors. This review focu-
ses on mechanistic aspects of the function of BRCA1 in
HR repair following replication stress, and also the im-
plications to tumor development and cancer therapy.
HR mediated repair can be triggered by DNA DSBs
and blockages of DNA replication. The process of repai-
ring DNA DSBs by HR has been extensively studied in
both lower and higher organisms. In general, recom-
bination is initiated at DSBs with the nucleolytic degra-
dation of DNA ends to generate 30-end ssDNA. This
reaction is carried out by the MRE11/RAD50/NBS1
(MRN) complex [2,3]. CtIP plays a critical regulatoryhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[4]. Once ssDNA is generated, it is rapidly bound by
the ssDNA-binding-protein RPA, a protein consisting
of three subunits: RPA1, RPA2 and RPA3. Through the
action of recombination mediator/comediator proteins,
RPA coated ssDNA is displaced by the RAD51 protein, a
human homologue of E. coli RecA. The formed RAD51
nucleoprotein filament facilitates DNA strand invasion
and exchange steps [5] which leads to formation of a
Holliday junction (HJ) (Figure 1). From this point, the
DSBR (double-strand break repair) pathway and the
SDSA (synthesis-dependent strand annealing) pathway
are defined. They are two primary models for how HR
repairs two ended DSBs [6]. In the DSBR pathway, the
second 30 overhang also forms an HJ with the homolo-
gous chromosome, which most frequently is a sister
chromatid. Whether recombination in the DSBR path-
way results in crossover is determined by how the dou-
ble HJs are resolved by a restriction endonuclease, a
resolvase [7], which cuts only one DNA strand. RAD51C
is an identified resolvase in mammalian cells [8]. Cross-
over occurs if one HJ is cut on the crossing strand and
the other HJ is cut on the non-crossing strand (Figure 1).
Alternatively, if the two HJs are cut on the crossingFigure 1 DSBs can be repaired by several HR repair pathways includi
dependent strand annealing). HR is initiated by resection of a DSB to pro
overhangs into a homologous sequence is followed by DNA synthesis at th
end can be captured to form an intermediate with two HJs. After gap-repa
non-crossover (red arrow heads at both HJs) or crossover mode (orange ar
Alternatively, the reaction can proceed to SDSA by strand displacement, an
break end, followed by gap-filling DNA synthesis and ligation. The repair pstrands, gene conversion (GC) occurs without a cross-
over [9]. The DSBR pathway more frequently results in a
crossover than GC (Figure 1). In the SDSA pathway,
only GC occurs because the first invading 30 strand is
extended along the recipient DNA duplex by a DNA
polymerase, and is released as the HJ resolves via branch
migration.
DNA replication-associated lesions are repaired by
HR via crossover
The lesions occurring at stalled/collapsed replication
forks can be repaired by HR or bypassed by translesion
DNA synthesis (TLS). The HR mechanism required for
repairing lesions at stalled or collapsed DNA replication
forks in mammalian cells is less well-understood com-
pared to the pathways identified in bacteria and yeast.
There are several models available depending on whe-
ther the lesion occurs in the leading or lagging strands.
If the lesion occurs in leading strands, stalled replication
forks can be cleaved by an endonuclease, leading to the
creation of a one-sided DSB. Similar to the RuvABC
complex in E. coli [10], the endonuclease Mus81 faci-
litates one ended DSB generation in mammalian cells
[11,12]. One-sided DSB repair by recombination involvesng DSBR (double-strand break repair) and SDSA (synthesis-
vide 3’ ssDNA overhangs. Strand invasion by these 3’ ssDNA
e invading end. After strand invasion and synthesis, the second DSB
ir DNA synthesis and ligation, the structure is resolved at the HJs in a
row heads at one HJ and red arrow heads at the other HJ).
nealing of the extended single-strand end to the ssDNA on the other
roduct from SDSA is always non-crossover.
Figure 2 Pathways of HR repair at stalled/ collapsed replication forks. (A,B,C) Possible pathways resolving leading-strand blockages by HR.
Stalled replication forks can be cleaved by an endonuclease to generate a one-sided DSB (A) which can be repaired by HR and re-establishment
of a functional fork. Resolution of the single HJ in the orientation shown by the orange arrows results in SCE. Alternatively, a one sided DSBs can
be converted into two sided DSBs by encountering a second replication fork; subsequently two end DSBs trigger HR by formation of double HJs
(B). Moreover, uncoupling of lagging-strand synthesis can lead to downstream re-initiation of leading strand synthesis, resulting in a leading
strand gap, which can be repaired by HR. In this situation, no DSBs are created (C). (D) Possible pathway resolving lagging strand blockage.
Downstream re-initiation of lagging-strand synthesis after blockage leaves a gap on the lagging strand which can be repaired by HR.
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A crossover is generated when the HJ structure is re-
solved [13]. Alternatively, a one-ended DNA DSB could
subsequently progress to a two-ended DSB due to the
firing of a new origin of replication under conditions of
replication stress, and HR will be initiated to repair a
structure that is similar to the classical two-end DSB
(Figure 2B) [14]. In both situations (Figure 2A,B), DSBs
are involved. In contrast, no DSBs are generated if
uncoupling of continued lagging-strand synthesis with
stopped leading strand synthesis occurs. Downstream
re-priming of leading strand synthesis will result in the
leading strand gap, and can be subsequently be repaired
by recombination [10,15,16] (Figure 2C). If a lesion leads
to lagging strand blockage (Figure 2D) the replication
fork may not collapse. Downstream re-priming of lag-
ging-strand synthesis after blockage leaves a gap on the
lagging strand, which can be repaired by recombination
[10]. Although it was reported that creation of DNA
DSBs leading to replication fork collapse is a major me-
chanism to initiate HR in mammalian cells [14,17], it
has been demonstrated that thymidine can potently in-
duce HR in the absence of DSBs even after long term
exposure [18]. Recent work from our lab showed that
sister chromatid exchange (SCE, see discussion below) isinduced when the cells are treated with 2 mM hydro-
xyurea (HU) for 6 hr , a condition in which no DSBs are
detected by Comet assay or FISH [19]. Similar to lower
organisms, therefore, HR can be induced in the absence
of free DNA DSB ends in mammalian cells.
Broken replication fork-stimulated HR may be dif-
ferent than HR induced by classical two-end DNA
DSBs. Two-end DNA DSBs created by site-specific I-SceI
endonuclease overexpression in mammalian cells triggers
HR repair by short gene conversion [20], whereas spon-
taneous HR, most likely occurring at replication forks,
triggers repair via a SCE [21,22]. In addition, the product
of HR induced by replication stress is SCE/long tract gene
conversion [21,22]. Moreover, we have found that phos-
phorylation of RPA2 is specifically required for HR in re-
sponse to replication arrest, but is not essential for the
cutting two-end DSBs induced HR [23]. Further, GC
detected by an I-SceI based HR reporter is promoted by
ATR, while SCE induced by replication fork collapse is
suppressed by ATR [19]. These studies suggest that HR
pathways required for repairing direct DSBs and repli-
cation blockage are distinct. Furthermore, HR pathways
required for repairing replication fork stalling and collapse
appear to be different as well. We have found that SCE
induced by DSBs following fork collapse is suppressed by
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tion fork stalling is similar in cells with or without ATR
depletion [19]. The complexity of the HR pathway was
further increased by the observation that mouse cells lack-
ing DNA POLβ, the major gap-filling DNA polymerase,
display higher than normal SCE levels following alkylating
agent exposure, although they exhibit normal levels of
spontaneous SCE [13]. Also some HR proteins required
for replication stress-induced SCE have no obvious effect
in spontaneous SCE (see discussion below). In summary,
HR repair pathways triggered during DNA replication
blockage are differently regulated than those induced by
direct DNA DSBs. In addition, several subtypes of the HR
pathway exist to deal with spontaneous and induced DNA
lesions resulting from replication fork stalling or collapse.
SCEs are associated with DNA replication and HR
HR requires a template with sufficient sequence identity
to the damaged strand in order to direct repair. In mam-
malian cells, the sister chromatid is the primary template
for HR compared to the homologous chromosome [20].
SCEs occur naturally as events associated with normal
DNA replication and upon replication fork stalling/col-
lapse. Formation of SCEs is intimately associated with
DNA replication because eukaryotic cells exposed to
DNA-damaging agents in G2 show elevated SCE levels
only after completing a subsequent replication cycle [24].
Although the molecular mechanisms controlling SCE
are not fully understood, HR between sister chromatids
is principally responsible for SCE in higher eukaryotic
cells [25]. This process is considered to be conservative
and error-free, since no information is generally altered
during reciprocal interchange by HR. It is known that
not all types of DNA damage give rise to SCE. DNA
DSB agents can not efficiently induce SCEs. In contrast,
SCEs can be induced by various genotoxic treatments
causing replication arrest. S phase-dependent agents, such
as mitomycin C (MMC) and UV light are among the most
effective inducers of SCE [26], presumably the conditions
that increase the cellular burden of SSBs or subsequent
DSBs creation during replication stress generally induce
SCE efficiently. Thus, the simplest pathway by which SCE
likely occurs is through HR-mediated restart of a broken
DNA replication fork when it encounters a nick or gap in
one parental strand [13] (Figure 2A).
Many HR proteins have been reported to promote
SCE in chicken DT40 cells. HR defective mutants, in-
cluding mutants of RAD51, RAD54, and the RAD51
paralogs (i.e. RAD51B, C, and D and XRCC2), consis-
tently have reduced SCE [25] [27]. However, in mamma-
lian cells, the results are more complex. Rad54 knockout
mice cells show little or no reduction in spontaneous
SCE, but there is a noticeable deficiency in MMC-
induced SCE [28,29]. Moreover, some RAD51 paralogmutants show modest reductions in SCE, but isogenic
rad51d mutant lines in both chinese hamster ovary and
mouse fibroblasts show no decrease in spontaneous
SCE [29,30]. Consistent with these studies, we obser-
ved that BRCA1 has no obvious role in spontaneous
SCE (unpublished data), although BRCA1 promotes
replication-stress induced SCE. Although HR is con-
sidered to be the pathway for formation of SCEs, the
observation that in HR-deficient cells, the background
SCE levels are comparable to the parental cells sug-
gests that spontaneous SCEs do not originate from HR.
On the contrary, HR seems to be involved in the forma-
tion of induced SCEs [31]. In summary, the variation in
phenotypes between spontaneous and induced SCE sug-
gests that more than one molecular pathway is responsible
for SCE in response to replication stress.
In contrast to HR proteins, several proteins were
found to suppress SCE. The helicase protein, BLM, ap-
pears to be important in this process since loss of the
BLM gives rise to an elevated frequency of SCE during
DNA replication [32]. BLM suppresses SCE via multiple
processes, including through association with topoiso-
merase IIIα (hTOPO IIIα) [33-35] and/or RAD51 [36]
[37]. It has been suggested BLM and hTOPO IIIα
together effect the resolution of a recombination in-
termediate containing a double Holliday junction[38].
Although it is believed that BLM works as an anti-re-
combinase, in Drosophila DmBlm was found to be re-
quired specifically to promote the SDSA, a type of HR
associated with GC but not cross-over (Figure 1). This
result was confirmed in the chicken DT40 B lymphocyte
line by demonstrating that Ig GC frequency was drastic-
ally reduced in BLM−/− cells [39]. Thus, BLM suppresses
SCE but promotes GC.
Recent work in our lab showed that ATR suppresses
SCE upon replication fork collapse, although ATR has
no role in SCE when the replication forks stall [19]. HU,
which functions as an inhibitor of ribonucleotide reduc-
tase, slows down fork progression by reducing dNTP
pools, leading to stalled replication forks that after pro-
longed treatment collapse into DNA DSBs [14]. We
found that ATR depletion leads to an increased rate of
SCE in the cells treated with HU for 18 hr when DSBs
are efficiently created. Conversely, ATR depletion sup-
pressed I-SceI-induced GC [19]. Although it is not clear
how ATR suppresses SCE, there are several possibilities.
First, the similar effect of ATR and BLM deficiency on
SCE and GC suggest that both proteins act in the same
pathway, presumably ATR suppresses SCE via regulation
of BLM. BLM is phosphorylated by ATR on two resi-
dues, Thr99 and Thr122, and has a role in the recovery
from S-phase (16) [40]. Surprisingly expression of BLM
containing T99A and T122A substitutions in human
BLM defective cells was able to suppress the hyper-SCE
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BLM, indicating that substitution of Thr99 and Thr122
with alanine did not prevent BLM from suppressing
spontaneous SCE [40]. Thus, BLM phosphorylation by
ATR has no direct role in spontaneous SCE. However,
the possibility that BLM phosphorylation by ATR is im-
portant to SCE induced by replication stress has not
been tested. Alternatively, the SCE repression by ATR
may operate in part by impeding the resection of cutting
free DNA ends. It has been reported that the MEC1 rep-
lication checkpoint suppresses the formation of RAD52
foci and prevents HR at chromosome breaks induced by
the HO endonuclease in yeast [41]. This repression
operates at least in part by impeding resection of DNA
ends, which is essential to generate the 30 ssDNA tails
that are the primary substrate of HR. Interestingly, the
MEC1 pathway does not prevent recombination at stalled
forks, presumably because they already contain ssDNA
[41], which is consistent with that the concept that ATR
has no role on SCE following replication fork stalling but
suppresses SCE following fork collapse after DSBs are pro-
duced [19]. Lastly, the elevated SCE frequency following
ATR depletion may be related to the specific locations
where the increased breakages occur. Chromosomal fragile
sites are the regions of the genome which exhibit gaps or
breaks on metaphase chromosomes under conditions of
partial replication stress [42]. Common fragile sites with or
without associated breakages are the preferred location for
SCE in aphidicolin treated cultures [43,44]. SCEs were
found to be distributed nonrandomly across fragile sites
and nonfragile sites; and among the fragile sites, the high
frequency SCE sites were highly correlated with the high
frequency breakage sites [44], indicating that SCE are pre-
ferentially induced at common fragile sites with broken
ends. ATR protein was found to bind to three regions of
FRA3B under conditions of replication stress, and a defi-
ciency of ATR results in a dramatic increase in fragile site
breakage [45,46]. Thus, defective ATR signaling could re-
sult in DNA breakages at the sites which are the hotspots
for SCE.
The role of BRCA1 in HR
Germ line mutations in BRCA1 confer increased suscep-
tibility of developing breast cancer with high penetrance
[47,48]. BRCA1 function may also be lost in a substantial
number of sporadic breast cancers [49-52]. The BRCA1
protein contains multiple functional domains, including
a highly conserved N-terminal RING finger which con-
tributes to its E3 ligase activity. BRCA1 interacts directly
or indirectly with numerous molecules [53], which is con-
sistent with the observation that BRCA1 deficiency results
in pleiotropic phenotypes, including defective DNA dam-
age repair, defective cell cycle checkpoints, increased
apoptosis, impaired spindle checkpoint and chromosomedamage [54,55]. Although it is not clear if all observed
phenotypes contribute to BRCA1 mutations associated tu-
morigenesis, the function of BRCA1 in HR repair plays a
critical role in BRCA1 associated cancer development
[55,56].
The observation that BRCA1 associates and colocalizes
with RAD51 in nuclear foci in mitotic cells is one of the
earliest indications that BRCA1 functions in HR repair
[57]. These foci have been observed before and after DNA
damage [58-60], indicating the role of BRCA1 in repair
of intrinsic or induced DNA damage. Further evidence
comes from the observation that BRCA1-deficient cells
are highly sensitive to IR and display chromosomal in-
stability including chromatid breaks, a chromosome ab-
breviation frequently observed in cells with HR deficiency
[61,62]. There is direct evidence that BRCA1 plays a role
in HR. Two reports found that BRCA1 deficiency in
mouse embryonic stem cells leads to decreased HR repair
of direct DSBs induced by the site-specific I-SceI endo-
nuclease [63,64]. Impaired HR in human cancer cells
depleted of BRCA1 using a similar HR reporter has also
been observed [65]. In addition there is a report implicat-
ing BRCA1 in Ig GC [66]. While the focus of BRCA1 in-
vestigation has been on DSB processing, its potential role
in dealing with replication stress is relatively less explored.
The observation that BRCA1 is required for subnuclear
assembly of RAD51 and survival following treatment with
a DNA damaging agent that does not cause DNA DSBs
suggests that BRCA1 is involved in HR upon replication
fork stalling. Our recent work has suggested that both
BRCA1 and RAD51 proteins are co-localized with ssDNA
regions following HU treatment for 6 hr when no DSBs is
detected. In addition, a reduced proportion of cells with
RAD51 foci and SCE frequency were observed in the cells
with BRCA1 depletion under the same conditions. This
observation suggests a role of BRCA1 in HR via regulation
of RAD51 recruitment in the absence of DNA DSBs [19].
This study was the first to shed light on how BRCA1 defi-
ciency influences HR repair in the context of a stalled rep-
lication fork. In addition, a recent report by Pathania et al.
demonstrated that BRCA1 is important in dealing with
UV-induced DNA lesions without detectable DNA DSBs
[67]. In the model proposed by the authors, the UV
sensitivity of BRCA1-deficient cells may be a compound
phenotype from the perturbed intra-S phase and G2/M
checkpoints, lesion removal, and TLS. However, given the
fact that SCE can be induced by UV light [68] and HR con-
tributes to cell viability after UV-light treatment [69], the
role of BRCA1 in SCE at stalled replication forks would be
an alternative mechanism contributing to the observed UV
sensitivity in BRCA1-deficient cells. In addition to the role
in SCE at stalled replication forks, BRCA1 is important for
SCE produced by fork collapse as well. However, the role
of BRCA1 in replication fork collapse-induced SCE is
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ing SCE following replication fork stalling is intact with or
without ATR depletion. Thus, we conclude that BRCA1
facilitates SCE via distinct mechanisms when replica-
tion forks stall or collapse. Interestingly, it has been
previously demonstrated that BRCA2-defective ham-
ster cells are impaired in short tract GC but maintain
proficiency in SCE [70]. Thus, it would be very interest-
ing to test how BRCA2 regulates SCE when ATR is
defective.
The question of why BRCA1 plays a profound role in
replication fork collapse-induced SCE in cells with ATR
deficiency remains open. One possibility is that SCE rate
is very low in the normal context because inappropriate
template choice within a sister chromatid leads to un-
equal SCE leading to gene duplication or deletions, which
are associated with tumorigenesis [71]. However, SCE
becomes a major mechanism to repair DNA DSBs when
cells with a defective checkpoint signaling are challenged
by replication stress. Therefore, the role of BRCA1 in
SCE-associated HR is not evident unless ATR is depleted.
Alternatively, loss of ATR may provide ideal substrates for
BRCA1 in HR. BRCA1 promotes repair of DSBs following
replication fork collapse via multiple mechanisms whereas
BRCA1 promotes HR following replication fork stalling
solely via the facilitation of ssDNA resection (see discus-
sion below). Last, ATR may play a direct role in BRCA1-
dependent SCE following replication fork collapse via
phosphorylation of BRCA1. However, it is unclear how
ATR-dependent phosphorylation of BRCA1 alters BRCA1
activities in SCE when replication arrests.
Of note, recombination related processes have a cen-
tral function in the recovery of stalled or collapsed repli-
cation forks in both bacteria and eukaryotic cells [10,72].
For example, the endonuclease Mus81 in mammalian
cells contributes to replication restart by promoting HR
via facilitation of one-ended DSBs generation [12]. How-
ever, it was reported recently that HR facilitates repair of
DSBs following fork collapse but does not necessarily
contribute to replication fork restart in mammalian cells
[14]. It was found that stalled replication forks are effi-
ciently restarted in a RAD51-dependent process that
does not trigger HR. In contrast, replication fork col-
lapsed by prolonged replication blocks do not restart,
and global replication is rescued by new origin firing.
Thus, it would be very interesting to evaluate whether
the role of BRCA1 in SCE contributes to recovery of
stalled/collapsed replication forks.
BRCA1 function in HR: a recombination mediator/
comediator and promoting ssDNA resection
The interaction of both BRCA1 and BRCA2 with RAD51
suggests a functional link between the three proteins in
the RAD51-mediated DNA damage repair process.However, while BRCA2 is directly involved in RAD51-me-
diated repair, BRCA1 seems to act in a more complicated
mechanism via an interaction with other proteins [73,74]
(Figure 1). Although the mechanisms by which BRCA1
functions in HR have not been clear, studies have sug-
gested that BRCA1 acts as a recombination mediator/
comediator, and promotes ssDNA resection via interac-
tion with CtBP-interacting protein (CtIP). Recombination
mediators are proteins facilitating displacement of RPA by
RAD51 by binding RAD51 and possess a high affinity for
ssDNA [5]. The mediators help overcome the suppressive
effect of RPA by targeting RAD51 to free DNA or DNA
already covered with RPA. To assist these recombination
mediators, a second group of proteins is required and we
define these proteins here as ‘recombination co-mediators’
[75]. BRCA2 is a well-defined mediator by direct inter-
action with RAD51 protein. RAD52 may function as an
HR mediator when BRCA2 is absent in mammalian cells
[76]. In general, in the absence of mediator/comediator,
RAD51 overexpression can partially compensate. BRCA1
might act as a mediator/comediator since overexpression
of RAD51 in BRCA1-deficient DT40 cells rescues defects
in proliferation, DNA damage survival, and HR support
[75,77]. A second molecular mechanism by which BRCA1
acts in HR is via association with CtIP [78]. The work
from Yun et al. suggested that the function of CtIP in HR
induced by I-SceI overexpression is dependent on BRCA1
recruitment and the phosphorylation of S327, which med-
iates its interaction with BRCA1 [79,80]. Cells expressing
CtIP protein that cannot be phosphorylated at S327 are
specifically defective in HR and have a decreased level of
ssDNA induced by X-rays. The report supports a model
in which phosphorylation of CtIP S327 as cells enter S
phase, and the recruitment of BRCA1, functions as a mo-
lecular switch to shift the balance of DSB repair from
error-prone DNA end- joining to error-free HR via facili-
tating ssDNA resection [78]. The possibility that BRCA1
functions in ssDNA resection via association with CtIP
during DNA replication arrest came from our recent pub-
lication [19]. We found that CtIP depletion leads to a
similar pattern in SCE formation when replication fork
arrest compared to those occurring in cells with BRCA1
depletion, namely CtIP knockdown leads to decreased fre-
quency of SCE following replication fork stalling inde-
pendent of ATR. In contrast, the CtIP knockdown leads to
an obviously decreased SCE frequency in cells depleted of
ATR after 18 hr HU treatment when obvious DSBs are
generated, although it has only a minor effect on SCE for-
mation in cells with intact ATR expression. This result is
similar to that observed in cells with BRCA1 knockdown,
indicating that CtIP may function in the same pathway as
BRCA1 [19].
The questions of whether the molecular mechanism
by which BRCA1 promotes SCE after replication fork
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However, it appears that BRCA1 may function differen-
tially [19]. We found that BRCA1 depletion leads to a
decreased RPA2-phosphorylation by immunoblotting in
cells following 6 hr of HU treatment in the absence of
detectable DNA DSBs. Conversely, BRCA1 depletion
had no obvious effect on RPA2-phosphorylation in cells
following 18 hr of continuous HU treatment. The likely
scenario is that loss of BRCA1 leads to a defect in
ssDNA resection when replication forks stall, which re-
sults in the impaired RPA2-phosphorylation. However,
when replication forks collapse, BRCA1 also functions as
a mediator of RAD51, and the loss of BRCA1 should
lead to increased RPA2-phosphorylation due to a defect-
ive RAD51 recruitment, counteracting the decreased
RPA2 phosphorylation resulting from impaired ssDNA
resection. Thus, the levels of RPA2 phosphorylation are
similar in cells with or without BRCA1 depletion when
replication forks collapse. The idea that ssDNA resection
occurs during replication stalling is supported by evi-
dence from both bacteria and mammalian cells. In E.coli,
ssDNA resection is required to enlarge the ssDNA gap
for RAD51 dependent HR [81]. Studies in mammalian
cells have shown the existence of ssDNA gaps during
stalled DNA replication in UV-damaged S phase cells
[82,83]. RPA-coated ssDNA regions upon UV damage
were much reduced in the absence of BRCA1 [67], sug-
gesting a role for BRCA1 in DNA resection when repli-
cation forks stall. A model for the role of BRCA1 in HR
in response to replication fork stalling or collapse has
been proposed in our recent publication [19].
The function of BRCA1 in ssDNA resection is re-
gulated by 53BP1 and RPA80. The crosstalk between
BRCA1 and 53BP1 in ssDNA resection has been high-
lighted in recent studies. These studies showed that
53BP1 inhibits HR in BRCA1-deficient cells via a block-
ing resection of DNA breaks [84-86]. Unlike Brca1
mutants, Brca1/53BP1 double mutants are proficient for
HR, and assemble RPA foci after DNA damage, arguing
that the primary function of BRCA1 in DSB repair is to
promote resection by antagonizing 53BP1. These studies
also found that loss of 53BP1 restores the deficiency of
PARP inhibitor induced SCE in MEF cells with BRCA1
deficiency [84]. Thus, it would be very interesting to de-
termine how 53BP1 affects the role of BRCA1 in SCE
formation in response to replication fork stalling or col-
lapse in the future. In addition, a recent study from Hu
et al. suggests that RAP80 contributes to the suppression
of exaggerated, BRCA1-dependent HR activity [87]. It
was found in this study that the rate of SCE induced by
etoposide, a potent DSB inducer, is higher in RAP80-
depleted cells compared to that observed in control cells.
Thus, RAP80/BRCA1 complexes suppress excessive DSB
end processing. However, the available data cannotexplain how 53BP1 and RAP80 function in the different
settings. For instance, the regulation of 53BP1 in ssDNA
resection occurs in BRCA1 deficient cells. In contrast,
suppressing BRCA1-driven HR by RAP80 can occur in
cells with intact BRCA1. Further studies are needed to
address these questions.
A very recent publication suggests BRCA1-associa-
ted exclusion of 53BP1 from DNA damage sites from
examining the spatial distribution of BRCA1 and 53BP1
proteins within single IR induced focus (IRIF) by emplo-
ying a novel super-resolution microscopy: three di-
mensional structured illumination microscopy [88]. The
authors found that as cells transition through S-phase the
recruitment of BRCA1 into the core of IRIF, which they
assume involves HR, is associated with an exclusion of
53BP1 to the focal periphery, leading to an overall reduc-
tion in 53BP1-chromatin occupancy. The same pattern
was also observed after treatment with camptothecin, a
Topoisomerase I inhibitor that induces DSBs in S-phase
when replication forks encounter trapped Top1-DNA
cleavage complexes. Therefore, the authors propose that
BRCA1 antagonizes 53BP1-dependent DNA repair in
S-phase by inhibiting its interaction with chromatin
proximal to damage sites. How the molecular choreog-
raphy of 53BP1, BRCA1 and other proteins take place
and how this physical distribution in a focus affects the
function of BRCA1 in HR, however, is not yet clear.
Is BRCA1 E3 activity required for HR?
One of the functions of BRCA1 is as an E3 ligase.
BRCA1 ubiquitin ligase activity is observed when BRCA1
forms a heterodimeric complex with BARD1 [89]. The po-
tential importance of the E3 ligase activity of BRCA1
in cellular pathways is supported by the observation that
missense mutations within RING finger domain of
BRCA1, which cause familial breast cancer, abolish the E3
activity [89-93]. The role of BRCA1 E3 activity in HR has
been reported in several publications. BRCA1 transgenes
with E3 ligase mutations are unable to restore HR in
BRCA1 defective cells using I-SceI based HR reporters
detecting GC [91,94]. In addition, the investigation of
multiple mutants of BRCA1 from patients that disrupt
the interaction of E2 enzymes without perturbing the
BRCA1–BARD1 complex has revealed that E3 ligase ac-
tivity strongly correlates with BRCA1 functions in HR,
and breast cancer susceptibility [77,94]. Interestingly, ma-
ny studies have suggested a role for the E3 ligase activity
of BRCA1 in HR in repairing two-ended DSBs. However,
surprisingly, genetically engineered mouse ES cells expres-
sing BRCA1 with a substitution of alanine for isoleucine
at position 26 (I26A), a frequent mutation that disrupts
the binding to the E2 subunit without perturbing BARD1
binding [90], do not exhibit HR failure [95]. The ES cells
with BRCA1 I26A are resistant to genotoxic stress and are
Zhang Cell & Bioscience 2013, 3:11 Page 8 of 14
http://www.cellandbioscience.com/content/3/1/11capable of accumulating RAD51 at DSBs, and mediate HR
repair at the same level as cells with wild type BRCA1.
This report questions the importance of E3 ligase activity
of BRCA1 to HR. However, the same study also de-
monstrated that an E3 ligase mutation in BRCA1 leads
to a decrease in recombination mediated gene targeting
[95]. Since it has been shown that gene targeting occurs
through a process in which only a one-ended DSB is
involved [96], it is possible that the E3 ligase activity of
BRCA1 is only required for HR induced by a one-ended
DSB but is not important for HR induced by two-ended
DSBs. So it is possible that the E3 ligase activity of BRCA1
is required for the HR process in response to some spe-
cific types of DNA damage, such as HR triggered when
replication forks are blocked. This hypothesis is supported
by the same study demonstrating that the ES cells expres-
sing inactive BRCA1 E3 ligase show an elevated level of
damage-induced, but not spontaneous, chromosomal ab-
normalities [95]. To clarify the mechanisms behind these
observations, there is a need to study systematically how
E3 ligase activity of BRCA1 regulates HR under replica-
tion stress conditions. Any advances in this topic would
advance the current knowledge of BRCA1 associated
breast cancer development.
The role of BRCA1 in HR in response to replication
stress and tumor prevention
A phenotypic hallmark of cells with mutations in genes
involved in HR is chromosome instability. In the absence
of HR, the resulting phenotypes can be seen either by
spectral karyotyping (SKY) or by array-comparative ge-
nomic hybridization (aCGH), which detects large los-
ses and gains across the genome that are common in
BRCA1-deficient cells [73]. Genomic instability follow-
ing loss-of-function of BRCA1 is hypothesized to be a
key factor leading to tumorigenesis in individuals with
BRCA1 mutations. It is generally believed that BRCA1
maintains genomic stability by promoting error free HR
and suppresses error prone NHEJ [97-99]. This idea was
further confirmed by a recent report demonstrating that
knockdown or loss of the BRCA1 protein results in an
increased frequency of plasmid DNA mutagenesis and
microhomology mediated end joining following a DSB,
suggesting that that BRCA1 protects DNA from muta-
genesis during nonhomologous DSB repair [100].
Tumorigenesis due to loss of BRCA1 is a consequence
of genetic instability. Numerical and structural aberra-
tions were initially found by SKY analysis in murine
embryos carrying a Brca1 null mutation [61]. Later, it
was observed that mouse embryonic fibroblast (MEF)
cells carrying a targeted deletion of exon 11 display exten-
sive chromosomal abnormalities and a defective G2/M
checkpoint [62]. Although the function of BRCA1 in HR
was not discussed in the study, chromatid breaks andquadriradial chromosome, two types of featured chromo-
somal aberrations frequently observed in cells with HR
deficiency, were observed in Brca1Δ11/Δ11 MEFs. The stu-
dies from a different group also suggested that spon-
taneous chromosomal instability, including chromatid
breaks and exchanges and chromosome breaks, dele-
tions, and translocations are significantly higher in
Brca1−/− cells as compared with Brca1+/+ [64]. Moreover,
dramatic chromosome aberrations were noted in cells de-
ficient in Brca1 [101]. All of the data uncover an essential
role of BRCA1 in maintaining genetic stability through
numerous functions including HR. Nevertheless, chromo-
some abnormalities in cells without BRCA1 may not ne-
cessarily result from dysfunctions in HR. A recent work
from Bunting et al. suggests that BRCA1 functions inde-
pendently of HR in DNA interstrand crosslink repair
[102]. The authors found that Brca1Δ11/Δ11 cells were
hypersensitive to two intra- or interstrand crosslinking
drugs, nitrogen mustard and MMC. 53BP1 depletion
restored HR in Brca1 Δ11/Δ11 cells but did not restore the
sensitivity and chromosome aberrations including chro-
mosome and chromatid breaks and radiation structures,
indicating that BRCA1 has a function in crosslink repair
and maintaining genomic stability during replication ar-
rest which is separate from its role in HR.
Loss of genes required for cell cycle checkpoints
and BRCA1 associated tumorigenesis
Cells with damaged DNA frequently arrest, which reduces
the probability of progressing to malignancy. Mutations in
checkpoint pathways can permit the survival or continued
growth of cells with genomic abnormalities, thus enhan-
cing the likelihood of malignant transformation [103].
This is no exception for BRCA1 mutation associated
tumor development. Loss of BRCA1 leads to embryonic
lethality. Multiple studies suggest that the p53 loss coop-
erates with the loss of BRCA1 in tumorigenesis [61,104-
109]. In addition, other genes required for cell cycle
checkpoint, including ATM, CHK2 and ATR, seem to be
important also for BRCA1-mutation tumorigenesis. Loss
of Atm or Chk2 rescues the embryonic lethality of Brca1
mutant mice and leads to the development of multiple
tumors [110]. In addition, ATM expression can be aber-
rantly reduced or lost in tumors expressing BRCA1 or
BRCA2 mutants compared with sporadic tumors without
BRCA1 or BRCA2 mutations [111]. Epidemiological evi-
dence implicates that Chk2 and BRCA1 are in the same
breast cancer prevention pathway [112], which is sup-
ported by the molecular process controlled by their inter-
action. Chk2 phosphorylates the serine 988 (S988) residue
of BRCA1 and co-localizes with BRCA1 within discrete
nuclear foci prior to DNA damage by γ-irradiation [113].
This phosphorylation is critical for the ability of BRCA1
to restore survival after DNA damage in BRCA1-mutated
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show that prevention of Chk2-mediated phosphorylation
via mutation of the S988 of BRCA1 disrupts both HR
detected by I-SceI reporter and the suppression of error
prone-NHEJ [97-99], supporting the hypothesis that
Chk2-dependent phosphorylation modulates the func-
tion of BRCA1 [97,99]. Moreover, uterus hyperplasia
and increased carcinogen-induced tumorigenesis in mice
carrying a targeted mutation of the Chk2 phosphorylation
site in BRCA1 has been reported [114], suggesting that
Chk2 phosphorylation is involved in the BRCA1 function
in repressing tumor formation. An interesting question
would be whether the role of BRCA1 in SCE induced by
replication arrest is regulated by Chk2 phosphorylation.
ATR signaling regulates several cell cycle checkpoints
and induces S-phase arrest in response to replication stres-
ses [115]. Although there is no data available for the role of
ATR in BRCA1 associated tumorigenesis in animal models,
a linkage of ATR with BRCA1 was suggested by earlier cell
biology and biochemistry studies. ATR can phosphorylate
BRCA1 on several residues [116-118]. Moreover, ATR
colocalizes with BRCA1 in foci in cells synchronized in S
phase and after exposure to DNA damaging agents or
DNA replication inhibitors, associating BRCA1 and ATR
with the response to stalled replication forks [117,118].
Furthermore, the dramatic relocalization of ATR nuclear
foci in response to DNA damage overlaps with the nuclear
foci formed by BRCA1. In addition to cell biology and bio-
chemistry studies, it has been reported that ATR was
down-regulated in BRCA1 mutation carriers following ra-
diation using high-density cDNA microarray technology
[119]. In this study, the expression profiles of breast
fibroblast samples from nine heterozygous BRCA1 mu-
tant carrier individuals were compared to the profiles of
five reduction mammoplasty fibroblast samples with a
very low probability of the presence of BRCA1 mutations
as controls. All of the samples were short-term primary
cultures, and were irradiated to induce sublethal DNA
damage. ATR was found to be down-regulated in muta-
tion carriers compared with the controls, indicating a po-
tential role of BRCA1 in ATR expression because of its
decreased transcription [119], and further suggesting that
ATR may be involved in BRCA1 associated tumorigenesis.
Since the function of BRCA1 in SCE following replication
fork collapse is more profound when ATR is depleted, this
could be another molecular mechanism explaining why a
second mutation in cell cycle checkpoint genes is import-
ant for BRCA1 associated cancer development in addition
to permitting survival of the cells with BRCA1 mutations.
The role of BRCA1 in HR following replication
stress: implications in PARP-inhibitor therapy
PARP inhibitors have been shown to be selectively lethal
to cells deficient in BRCA1 or BRCA2 due to syntheticlethality [120-123]. The PARP family consists of 17 pro-
teins based on structural similarity. PARP1 is the protein
that is best understood. This protein detects and binds
to sites of ssDNA damage, and then synthesizes poly
(ADP) ribose (pADPr, PAR) and transfers it to acceptor
proteins. The acceptor proteins include PARP1 itself and
other proteins involved in DNA repair, such as XRCC1,
a protein involved in BER [124]. However, a recent report
from Ström et al. suggested a distinct role of XRCC1 and
PARP inhibition in SSB repair [125]. No direct role for
PARP1 in BER was observed, but that PARP inhibitors
trap PARP on the SSB intermediate formed during BER.
Therefore, PARP1 plays an essential role in the latter steps
of BER ligation. It is widely believed that the reason that
recombination defective cells are sensitive to PARP inhibi-
tors is because GC-associated HR has an important role
in repairing a DSB. Thus, the increased number of un-
repaired endogenous SSBs in PARP inhibited cells result
in more collapsed replication forks, which require GC-
mediated HR for repair [126]. In a BRCA1/2 defective
background these DSBs are likely to be repaired by more
error-prone repair mechanisms, causing chromosome
aberrations and loss of viability [54]. However, the obser-
vations that SCE but not GC is the most frequent HR oc-
curring during replication stress suggest that SCE may be
more critical for repairing PARP1 inhibition associated
lesions. In addition, the results from Schultz et al. suggest
that GC following induction of a site-specific DSB is nor-
mal in PARP1-inhibited cells. In contrast, PARP1 inhib-
ition leads to an increase in crossovers as measured by
SCE frequency in culture [127]. Cells isolated from PARP-
1 knockout mice exhibit a hyper recombination pheno-
type and genetic instability in the form of increased levels
of SCE, micronuclei and tetraploidy [128,129]. Moreover,
the study from Bunting et al. also demonstrated that
PARP inhibition caused an increased SCE in MEF cells
[84]. All of these studies suggest that SCE is involved in
repairing DNA lesions caused by PARP inhibition. BRCA1
promotes SCE-mediated HR in response to replication
stress, which could be a mechanism explaining why
BRCA1 deficient cells is hypersensitive to PARP inhi-
bitors. Therefore, it is most likely that without PARP1,
SSBs accumulate and then collapse replication forks to
initiate SCE-mediated HR. If a PARP1 deficient cell is
also deficient in BRCA1, SCE-mediated HR cannot
occur, and the cell then dies or undergoes error-prone
NHEJ (Figure 3). However, the possibility that the role of
BRCA1 in GC is important for cell killing induced by
PARP inhibitors cannot be excluded. In addition, it is also
important to recognize that PARP activity and other pro-
teins are also important for HR at stalled forks since it
has been recently reported that PARP1 collaborates with
MRE11 to promote replication fork restart, most likely by
recruiting MRE11 to the replication fork to promote
Figure 3 DNA lesions caused by PARP inhibitors lead to increased crossovers. DNA breaks are detected by PARP1 and PARP1 is active
in response to DNA breaks. In the cells with intact PARP1 activity, the ssDNA is efficiently repaired (A). However, when the PARP1 activity is
inhibited, unrepaired ssDNA breaks can be converted into elongated ssDNA (B) or subsequently into DSBs due to replication collapse (C). Both
DNA structures stimulate SCE via HR.
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for HU-induced HR and cell survival after replication
blocks [130].PARP1 resistance
Although PARP inhibitors displayed promising results
for killing cancer cells with BRCA1/BRCA2 deficiency,
there are several issues regarding PARP inhibitor-related
therapies. Like other chemotherapy, acquired resistance
to PARP inhibitors has been reported. The resistance to
PARP inhibitors has led to the failure of phase III clinical
trials in triple negative breast cancers[131]. Thus, there
is urgency for elucidating the mechanisms by which
resistance occurs. The acquired resistance to PARP in-
hibitors may be due to various mechanisms, including
reverting inherited mutations in BRCA2 [132,133], an
up-regulation of the Abcb1a/b gene encoding a P-gly-
coprotein efflux pump [134], and loss of 53BP1 which
leads to restoration of impaired ssDNA resection result-
ing from BRCA1 deficiency [84]. In support of the idea
that SCE-associated HR is required for repairing the
DNA lesions caused by PARP inhibitors, 53BP1 deple-
tion restores the decreased frequency of SCE because of
BRCA1 deficiency [84]. How to overcome the acquired
resistance to PARP inhibitors is a new direction for fu-
ture study; strategies to overcome acquired resistance to
PARP inhibitors has been discussed in review [124]. For
instance, it has been reported that 6-thioguanine select-
ively kills BRCA2-defective tumors and overcomes PARP
inhibitor resistance [135].A second issue regarding PARP inhibitor associated
therapy is that even if there is an observed sensitivity
to PARP inhibitors in cancer cells without functional
BRCA1, the difference is much smaller compared with
the difference reported previously on pre-cancerous cells
[136]. In addition, not all breast cancer patients with
BRCA1 mutations respond to PARP inhibitors [137] and a
substantial fraction of advanced BRCA1-mutant cancers
are resistant to these agents. Therefore, the potential fac-
tor(s) contributing the effectiveness of PARP inhibitors in
the cytotoxicity of breast cancer cells with mutant BRCA1
needs to be explored. Since SCE mediated HR appears to
be important to repair PARP inhibitor-induced replication
lesions, any factors which potentially regulate SCE should
have an effect on PARP inhibitor-associated cancer treat-
ment. The observation that the role of BRCA1 in promo-
tion of SCE following replication fork collapse is more
profound in cells depleted of ATR provides the possibility
of sensitizing cancer cells without functional of BRCA1 to
PARP inhibitors by ATR inhibitors. Thus, the status of cell
cycle checkpoints should be taken into account when
PARP inhibitors are applied.Conclusions and perspectives
Mitotic HR promotes genome stability through the pre-
cise repair of DNA DSBs and other lesions that are en-
countered during normal cellular DNA replication and
replication stress. Deficiency in HR provides a promising
target for cancer therapy. It has become apparent that
HR repair produced by replication arrest is different to
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the past, research has been focused on the role of BRCA1
in classical two ended DNA DSB repair by HR. Recent
studies suggest that BRCA1 is critical for several subtype
HR pathways following replication arrest. However, how
BRCA1 acts in HR when replication forks stall/collapse
has not yet been satisfactorily answered. Hence, further
studies are needed to focus on the regulatory mechanisms
of HR repair by BRCA1 in response to DNA replication
stress in different settings. Any advance regarding this
topic will benefit our understanding of the mechanisms
underlying BRCA1 associated tumorigenesis, as well as
the development of therapeutic approaches for cancer
patients with dysfunctional BRCA1.
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